which of the following is not a cryptocurrency, snippets

The latest progress of stamp duty in Hong Kong has come!Exempting the transfer of shares or units of REITs and the securities distribution business of option makers will enhance the competitiveness of Hong Kong REITs and reduce the transaction costs of option makers. Revising the stamp duty collection arrangement will promote the efficiency of stamping and stamp duty collection procedures in the paperless securities market environment.

Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.Quantum technology is one of the important directions of the next industrial revolution, and it is also one of the concepts that we have always suggested that everyone pay attention to. At present, it is in the initial stage, and the imagination space is huge. You can dig it well.The previous wave of adjustment of the Hang Seng Index was to step back on the long-term trend line at the daily level, which gained support and rebounded recently. Today, it closed above the offensive line, and the long-term trend at the daily level remains intact. On the monthly level, it fell below the offensive line last month, but it is above the offensive line at present, and it closed above 19,738 points this month. The problem is not big, and the long-term trend remains intact, and there is a basis for further strength.

A shares: the latest release of Shanghai Stock Exchange! Incremental funds are coming, and it is likely to continue to rise on Thursday!Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".